Deals
As a rule, medical device companies have to demonstrate some level of commercial viability if they’re going to go public. A few are able to…
Read More
Shire this week announced plans to acquire Foresight Biotherapeutics for $300 million. Robert Dempsey, Shire’s vice president and head of the company’s ophthalmic unit, kindly…
Read MoreWith three of the four sustained-release drug delivery products commercially available in the U.S. and Europe, pSivida just might prove Wall Street pundits correct and…
Read MoreMedtech companies in ophthalmology have made some significant strides in recent months. Second Sight and Glaukos, of course, staged IPOs in their pursuit of revolutionary…
Read More
The dry eye space has taken a few hits lately with disappointing clinical news on the biopharmaceutical front. But investors and entrepreneurs developing new treatments…
Read MorePhysicians have 45 days to review and dispute payments from industry. The Ophthalmology Innovation Summit opening on Thursday is clear evidence of the advances that…
Read MoreHealthcare stocks are outperforming the indices, and ophthalmic companies are helping to fuel a large part of that growth, Jeffrey Hoffman, Managing Director and Head…
Read MoreBuilding a successful biotech or biopharma company typically turns on a sentinel event — the pivot, as William J. Link, PhD, Managing Director of Versant…
Read MoreWhen the OIS started its digital showcase in 2012, there was only one company presenting in the category. “Today there are six—evidence that this area…
Read MoreSpeaking at the recent OIS@AAO meeting, American Academy of Ophthalmology EVP and CEO David W. Parke II, MD, highlighted health care system integration forces that…
Read MoreOphthalmic Surgeon, Eric D. Kanter, MD, of Retina-Vitreous Consultants, balances his work at his busy New Jersey practice with his commitments as a principal member…
Read MoreA Wall Street Journal analysis of venture capital commitments showed ophthalmology remained the strongest sector within healthcare. According to the Wall Street Journal, privately held…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")